PRLD
NASD Prelude Therapeutics, Inc.$3.96 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.96, $0.04 below the day’s high of $4.00
- YTD change
- +36.55%
- vs 20-day SMA
- -17.10%
- vs 200-day SMA
- +3.05%
Price ranges
Price & Performance
+0.89 (+28.99%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 95.8% away from all-time highs of $95.38
- PRLD is up 37% since the beginning of the year
- PRLD is up 189% over the past 12 months
- PRLD is down 28% over the past 1 month
- 8% of all PRLD investors are betting against PRLD
PRLD reads neutral: price sits above one of the two key moving averages, the 12-month move is +175.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.07
- Last 5 days
- -15.74%
- vs 8-day SMA
- -9.68%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.